Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Payables (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Payables for 13 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 15.81% to $23.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.2 million, a 15.81% decrease, with the full-year FY2025 number at $23.2 million, down 15.81% from a year prior.
  • Payables was $23.2 million for Q4 2025 at Iovance Biotherapeutics, down from $32.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $33.1 million in Q4 2023 to a low of $19.3 million in Q3 2023.
  • A 3-year average of $28.6 million and a median of $30.3 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: decreased 18.6% in 2024, then rose 14.74% in 2025.
  • Iovance Biotherapeutics' Payables stood at $33.1 million in 2023, then dropped by 16.95% to $27.5 million in 2024, then decreased by 15.81% to $23.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Payables are $23.2 million (Q4 2025), $32.2 million (Q3 2025), and $33.0 million (Q2 2025).